Medicus Pharma (NASDAQ:MDCX) Releases Earnings Results

Medicus Pharma (NASDAQ:MDCX) issued its quarterly earnings data on Friday. The company reported ($11.64) EPS for the quarter, missing the consensus estimate of ($6.68) by ($4.96), FiscalAI reports.

Medicus Pharma Price Performance

MDCX stock traded up $0.04 during trading on Friday, reaching $1.87. The company had a trading volume of 29,253 shares, compared to its average volume of 97,217. Medicus Pharma has a 52 week low of $1.70 and a 52 week high of $127.50. The business has a 50 day moving average of $6.14 and a 200 day moving average of $21.72. The company has a market cap of $2.36 million, a P/E ratio of -0.02 and a beta of 0.80.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. Alliance Global Partners restated a “buy” rating on shares of Medicus Pharma in a report on Monday, September 14th. Wall Street Zen raised Medicus Pharma from a “strong sell” rating to a “sell” rating in a research report on Saturday, October 31st. Finally, Weiss Ratings upgraded Medicus Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, October 30th. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $450.00.

Medicus Pharma Company Profile

Medicus Pharma Ltd. (NASDAQ:MDCX) is a life sciences company focused on acquiring, developing and commercializing pharmaceutical and medical products. The company seeks to identify therapies and healthcare technologies with potential for commercialization and works to advance them through regulatory, clinical and market-development processes.

Medicus Pharma’s activities are centered on specialty healthcare markets, including pharmaceutical and medical products designed to address unmet patient and provider needs.